Compare Keel Infrastructure Corp. Common Stock (KEEL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keel Infrastructure Corp. Common Stock vs Neurocrine Biosciences Inc — how do they compare? Keel Infrastructure Corp. Common Stock trades at $3.08 (market cap $1.93B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.4× Keel Infrastructure Corp. Common Stock's market cap, and Keel Infrastructure Corp. Common Stock is more actively traded (30,868,523 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Keel Infrastructure Corp. Common Stock for 1 Days and Neurocrine Biosciences Inc for 23 Days on average.
| KEEL | NBIX | |
|---|---|---|
Market Cap | $1.93B | $14.36B |
Volume | 30,868,523 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $6.66 | $185.50 |
52-Week Low | $1.71 | $123.10 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $2.25B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Keel Infrastructure Corp. Common Stock
Keel Infrastructure develops and owns digital and energy infrastructure for high-performance computing workloads. Its assets include data centers and power infrastructure that support AI computing.
Read more on KEEL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
